Solventum Corporation

Second-quarter sales were $2.2 billion, up 2.2% reported and 9.5% organic year over year. Gross margin was 60.1%, up 410 basis points from 56% last year, though excluding the $100 million tariff refund it was about 55.6%. Operating margin was 28.4%, and EPS was $2.55; management said EPS would have been $1.73 excluding the $0.34 advanced-order benefit and $0.48 tariff-refund benefit. Segment organic growth included MedSurg up 8.9%, Dental up 15.2%, and HIS up 5.4%. For 2026, the company raised organic sales growth to 2.5% to 3% (or 3.5% to 4% excluding SKU exits), operating margin to 22.2% to 22.7%, EPS to $7.10 to $7.20, and free cash flow to $200 million to $300 million. Management said Q3 will mostly reverse the $125 million advanced-order benefit and the $0.34 EPS benefit from Q2.

Bryan Hanson framed the quarter as evidence that the company is executing well despite transformation complexity, saying the team delivered ahead of plan on both the top and bottom line. He emphasized that the 3M separation is near the finish line, which he said will reduce distraction, free up resources, and improve free cash flow. He also highlighted the decision to pursue a separation of HIS as a value-maximizing move that would make Solventum a more focused MedTech company, while keeping support for HIS customers and employees intact.

Wayde McMillan said Q2 sales of $2.2 billion reflected strong underlying execution, but also significant noise from about $125 million of ERP advanced orders, which he said will mostly reverse in Q3. He detailed the margin profile, noting gross margin of 60.1% included a $100 million tariff refund and that excluding it gross margin was about 55.6%; operating margin was 28.4%, or about 21.7% excluding advanced-order timing and the tariff refund. He also cited $403 million in cash and equivalents, $4.7 billion of net debt, and $144 million of free cash flow, and said the company repurchased nearly 4 million shares for $288 million in the quarter. For 2026, he raised the outlook to organic growth of 2.5% to 3%, operating margin of 22.2% to 22.7%, EPS of $7.10 to $7.20, and free cash flow of $200 million to $300 million.

Analysts focused heavily on the new HIS separation announcement, asking about inbound interest, transaction form, timing, tax leakage, and whether HIS is highly integrated with the rest of Solventum. Management said it has already received inbound interest, believes HIS is not highly integrated, and is keeping the separation method flexible to maximize shareholder value and manage dilution. Questions also centered on demand trends and the impact of advanced orders; management said it is not seeing softness in procedures or business momentum, and that the Q2 advanced orders will mostly reverse in Q3. Later questions addressed capital allocation after any HIS transaction, and management said the plan remains balanced overall but would likely lean toward shareholder returns while preserving investment-grade ratings and keeping tuck-in acquisitions as the M&A model.